Daiichi Presses On With Lead Pexidartinib Trial Despite Liver Toxicity

Daiichi Sankyo is to continue with a multinational Phase III trial for its novel candidate for tenosynovial giant cell tumor despite cases of liver toxicity, but has stopped enrolment short of target and modified the protocol.